279 related articles for article (PubMed ID: 23826213)
1. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
[TBL] [Abstract][Full Text] [Related]
2. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
3. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
5. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
6. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
[TBL] [Abstract][Full Text] [Related]
7. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
8. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
9. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
Lavallée VP; Gendron P; Lemieux S; D'Angelo G; Hébert J; Sauvageau G
Blood; 2015 Jan; 125(1):140-3. PubMed ID: 25331116
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
11. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R
PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546
[TBL] [Abstract][Full Text] [Related]
12. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
13. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
15. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
16. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
Kataoka K; Kurokawa M
Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
[TBL] [Abstract][Full Text] [Related]
17. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
18. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
19. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
20. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]